OsteoporosisPhase 3NCT00205777
Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
A Phase 3 study testing Bazedoxifene Acetate in people with Osteoporosis, run by Pfizer at 375 sites in 30 countries.
Trial summary
The purpose of this study is to determine whether bazedoxifene acetate is safe and effective in the treatment of osteoporosis in postmenopausal women. Read more about this study
- Who is it for?
- Ages 55 to 80 years, women only
- Conditions the study is for
- Osteoporosis
- What is being tested?
- Bazedoxifene Acetate
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 7,609 participants
- Where
- 375 sitesin 30 countries
- Study dates
- Dec 2001to Sep 2010
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 80 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Must be at least 2 years postmenopausal
- Osteoporotic subjects without vertebral fracture who meet BMD criteria, or Osteoporotic subjects with vertebral fracture
Who cannot join
- Diseases that may affect bone metabolism
- Vasomotor symptoms requiring treatment
- Known history or suspected cancer of the breast
- Active or past history of venous thromboembolic events
Trial locations and contacts
375 sites in 30 countries.
375 sites in 30 countries
United States205 sites
Pfizer Investigational Site
Aberdeen, South Dakota, 57401
Pfizer Investigational Site
Akron, Ohio, 44312-1647
Pfizer Investigational Site
Akron, Ohio, 44313
Pfizer Investigational Site
Albuquerque, New Mexico, 87102
Pfizer Investigational Site
Albuquerque, New Mexico, 87106
Pfizer Investigational Site
Albuquerque, New Mexico, 87109
Pfizer Investigational Site
Altoona, Pennsylvania, 16602
Pfizer Investigational Site
Anaheim, California, 92801
Pfizer Investigational Site
Anderson, South Carolina, 29621
Pfizer Investigational Site
Augusta, Georgia, 30909
Pfizer Investigational Site
Aventura, Florida, 33180
Pfizer Investigational Site
Avon, Indiana, 46123
Pfizer Investigational Site
Bangor, Maine, 04401
Pfizer Investigational Site
Bangor, Maine, 4401
Pfizer Investigational Site
Bellaire, Texas, 77401
Pfizer Investigational Site
Belton, South Carolina, 29627
Pfizer Investigational Site
Berkeley, California, 94705
Pfizer Investigational Site
Bethesda, Maryland, 20817
Pfizer Investigational Site
Beverly Hills, California, 90211
Pfizer Investigational Site
Billings, Montana, 59101
Pfizer Investigational Site
Birmingham, Alabama, 35233
Pfizer Investigational Site
Birmingham, Alabama, 35249-7201
Pfizer Investigational Site
Birmingham, Alabama, 35294-3708
Pfizer Investigational Site
Bismarck, North Dakota, 58501
Pfizer Investigational Site
Bismarck, North Dakota, 58503
Pfizer Investigational Site
Boca Raton, Florida, 33432
Pfizer Investigational Site
Boise, Idaho, 83702
Pfizer Investigational Site
Boise, Idaho, 83704
Pfizer Investigational Site
Boise, Idaho, 83712
Pfizer Investigational Site
Boston, Massachusetts, 02115
Pfizer Investigational Site
Bozeman, Montana, 59715
Pfizer Investigational Site
Bridgeport, Connecticut, 06606
Pfizer Investigational Site
Brookline, Massachusetts, 02445
Pfizer Investigational Site
Brooklyn Center, Minnesota, 55430
Pfizer Investigational Site
Cadwell, Idaho, 83605
Pfizer Investigational Site
Camp Hill, Pennsylvania, 17011
Pfizer Investigational Site
Cape Coral, Florida, 33990
Pfizer Investigational Site
Centerville, Ohio, 45459
Pfizer Investigational Site
Champaign, Illinois, 61820
Pfizer Investigational Site
Charlotte, North Carolina, 28207
Pfizer Investigational Site
Charlotte, North Carolina, 28209
Pfizer Investigational Site
Charlotte, North Carolina, 28277
Pfizer Investigational Site
Cheyenne, Wyoming, 82001
Pfizer Investigational Site
Chicago, Illinois, 60612
Pfizer Investigational Site
Cincinnati, Ohio, 45236
Pfizer Investigational Site
Cincinnati, Ohio, 45249
Pfizer Investigational Site
Clearwater, Florida, 33761
Pfizer Investigational Site
Cleveland, Ohio, 44122
Pfizer Investigational Site
Dallas, Texas, 75230-2513
Pfizer Investigational Site
Dallas, Texas, 75230
Pfizer Investigational Site
Dallas, Texas, 75231
Pfizer Investigational Site
Dallas, Texas, 75243
Pfizer Investigational Site
Daytona Beach, Florida, 32114
Pfizer Investigational Site
Daytona Beach, Florida, 32117
Pfizer Investigational Site
Decatur, Georgia, 30033
Pfizer Investigational Site
Delray Beach, Florida, 33484
Pfizer Investigational Site
Duncansville, Pennsylvania, 16635
Pfizer Investigational Site
Evansville, Indiana, 47712
Pfizer Investigational Site
Evansville, Indiana, 47714
Pfizer Investigational Site
Evansville, Indiana, 47750
Pfizer Investigational Site
Fall River, Massachusetts, 02720
Pfizer Investigational Site
Fall River, Massachusetts, 02721
Pfizer Investigational Site
Fargo, North Dakota, 58103
Pfizer Investigational Site
Fargo, North Dakota, 58104
Pfizer Investigational Site
Flowood, Mississippi, 39232
Pfizer Investigational Site
Fort Myers, Florida, 33916
Pfizer Investigational Site
Fort Myers, Florida, 33919
Pfizer Investigational Site
Fresno, California, 93710
Pfizer Investigational Site
Fresno, California, 93720
Pfizer Investigational Site
Gainesville, Florida, 32601
Pfizer Investigational Site
Glendale, Arizona, 85306
Pfizer Investigational Site
Grand Rapids, Michigan, 49503
Pfizer Investigational Site
Grand Rapids, Michigan, 49546
Pfizer Investigational Site
Hamden, Connecticut, 06518
Pfizer Investigational Site
Henderson, Nevada, 89014
Pfizer Investigational Site
Holiday, Florida, 34690
Pfizer Investigational Site
Houston, Texas, 77030
Pfizer Investigational Site
Huntsville, Alabama, 35801
Pfizer Investigational Site
Idaho Falls, Idaho, 83404
Pfizer Investigational Site
Jackson, Mississippi, 39216
Pfizer Investigational Site
Jamestown, North Dakota, 58401
Pfizer Investigational Site
Jefferson City, Missouri, 65109
Pfizer Investigational Site
Johnstown, Pennsylvania, 15904
Pfizer Investigational Site
Kalamazaoo, Michigan, 49048
Pfizer Investigational Site
Kalamazoo, Michigan, 49048
Pfizer Investigational Site
Kansas City, Kansas, 66160-7136
Pfizer Investigational Site
Kettering, Ohio, 45459
Pfizer Investigational Site
La Jolla, California, 92037
Pfizer Investigational Site
Lake Worth, Florida, 33461
Pfizer Investigational Site
Lakewood, Colorado, 80227
Pfizer Investigational Site
Langhome, Pennsylvania, 19047
Pfizer Investigational Site
Largo, Florida, 33773
Pfizer Investigational Site
Lemoyne, Pennsylvania, 17043
Pfizer Investigational Site
Libertyville, Illinois, 60048
Pfizer Investigational Site
Lincoln, Nebraska, 68510
Pfizer Investigational Site
Longmont, Colorado, 80501
Pfizer Investigational Site
Louisville, Kentucky, 40207
Pfizer Investigational Site
Louisville, Kentucky, 40291
Pfizer Investigational Site
Lousiville, Kentucky, 40291
Pfizer Investigational Site
Lyndhurst, Ohio, 44124
Pfizer Investigational Site
Madison, Connecticut, 06443
Pfizer Investigational Site
Manchester Twp, New Jersey, 08759
Pfizer Investigational Site
Mayfield Village, Ohio, 44143
Pfizer Investigational Site
Memphis, Tennessee, 38104
Pfizer Investigational Site
Memphis, Tennessee, 38119
Pfizer Investigational Site
Memphis, Tennessee, 38120
Pfizer Investigational Site
Memphis, Tennessee, 38138
Pfizer Investigational Site
Meridian, Idaho, 83642
Pfizer Investigational Site
Milwaukee, Wisconsin, 53209
Pfizer Investigational Site
Milwaukee, Wisconsin, 53226
Pfizer Investigational Site
Minot, North Dakota, 58701
Pfizer Investigational Site
Minot, North Dakota, 58702
Pfizer Investigational Site
Missoula, Montana, 59801
Pfizer Investigational Site
Missoula, Montana, 59802
Pfizer Investigational Site
Missoula, Montana, 59804
Pfizer Investigational Site
Mobile, Alabama, 36608
Pfizer Investigational Site
Mt. Pleasant, South Carolina, 29464
Pfizer Investigational Site
Nashville, Tennessee, 37203
Pfizer Investigational Site
New Hyde Park, New York, 11042
Pfizer Investigational Site
New York, New York, 10029
Pfizer Investigational Site
Newark, Delaware, 19713
Pfizer Investigational Site
Newtown, Pennsylvania, 18940
Pfizer Investigational Site
Norfolk, Virginia, 23502
Pfizer Investigational Site
North Las Vegas, Nevada, 89030
Pfizer Investigational Site
Oakes, North Dakota, 58574
Pfizer Investigational Site
Oakland, California, 94612
Pfizer Investigational Site
Ocean City, New Jersey, 07712
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73102
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73112-4481
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73120
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73142
Pfizer Investigational Site
Ormond Beach, Florida, 32174
Pfizer Investigational Site
Palm Beach Gardens, Florida, 33410
Pfizer Investigational Site
Palm Desert, California, 92260
Pfizer Investigational Site
Palm Harbor, Florida, 34684
Pfizer Investigational Site
Palm Springs, California, 92260
Pfizer Investigational Site
Palm Springs, California, 92262
Pfizer Investigational Site
Palm Springs, California, 92263
Pfizer Investigational Site
Pembroke Pines, Florida, 33027
Pfizer Investigational Site
Pembroke Pines, Florida, 33029
Pfizer Investigational Site
Peoria, Illinois, 61614
Pfizer Investigational Site
Phoenix, Arizona, 85007
Pfizer Investigational Site
Phoenix, Arizona, 85013-3903
Pfizer Investigational Site
Phoenix, Arizona, 85013
Pfizer Investigational Site
Phoenix, Arizona, 85015
Pfizer Investigational Site
Phoenix, Arizona, 85016
Pfizer Investigational Site
Phoenix, Arizona, 85020
Pfizer Investigational Site
Phoenix, Arizona, 85027
Pfizer Investigational Site
Phoenix, Arizona, 85050
Pfizer Investigational Site
Plantation, Florida, 33324
Pfizer Investigational Site
Port Orange, Florida, 32127
Pfizer Investigational Site
Princeton, New Jersey, 08542
Pfizer Investigational Site
Rancho Mirage, California, 92270
Pfizer Investigational Site
Reno, Nevada, 89502-1196
Pfizer Investigational Site
Reno, Nevada, 89503
Pfizer Investigational Site
Riverdale, Georgia, 30274
Pfizer Investigational Site
Robbinsdale, Minnesota, 55422
Pfizer Investigational Site
Sacramento, California, 95816
Pfizer Investigational Site
Sacramento, California, 95817
Pfizer Investigational Site
Sacramento, California, 95825
Pfizer Investigational Site
Salt Lake City, Utah, 84102-3015
Pfizer Investigational Site
San Antonio, Texas, 78220
Pfizer Investigational Site
San Antonio, Texas, 78229-3894
Pfizer Investigational Site
San Antonio, Texas, 78229
Pfizer Investigational Site
San Diego, California, 92108
Pfizer Investigational Site
San Diego, California, 92120
Pfizer Investigational Site
Sarasota, Florida, 34231
Pfizer Investigational Site
Sarasota, Florida, 34239
Pfizer Investigational Site
Scottsdale, Arizona, 85251
Pfizer Investigational Site
Scottsdale, Arizona, 85254
Pfizer Investigational Site
Seattle, Washington, 98105-4631
Pfizer Investigational Site
Seattle, Washington, 98105
Pfizer Investigational Site
Seattle, Washington, 98133
Pfizer Investigational Site
Seattle, Washington, 98195
Pfizer Investigational Site
Sellersville, Pennsylvania, 18960
Pfizer Investigational Site
Shoreview, Minnesota, 55126
Pfizer Investigational Site
Silver Spring, Maryland, 20902
Pfizer Investigational Site
Sioux Falls, South Dakota, 57105
Pfizer Investigational Site
Spokane, Washington, 99204
Pfizer Investigational Site
St Louis, Missouri, 63141
Pfizer Investigational Site
St. Petersburg, Florida, 33710
Pfizer Investigational Site
Temple, Texas, 76504
Pfizer Investigational Site
The Bronx, New York, 10461
Pfizer Investigational Site
Tulsa, Oklahoma, 74135
Pfizer Investigational Site
Upland, California, 91786
Pfizer Investigational Site
Virginia Beach, Virginia, 23454
Pfizer Investigational Site
Waco, Texas, 76708
Pfizer Investigational Site
Washington D.C., District of Columbia, 20006
Pfizer Investigational Site
Washington D.C., District of Columbia, 20007-2197
Pfizer Investigational Site
Washington D.C., District of Columbia, 20007
Pfizer Investigational Site
Washington D.C., District of Columbia, 20037
Pfizer Investigational Site
Waterbury, Connecticut, 06708
Pfizer Investigational Site
Waterdown, South Dakota, 57201
Pfizer Investigational Site
Watertown, South Dakota, 57201
Pfizer Investigational Site
West Palm Beach, Florida, 33401
Pfizer Investigational Site
West Palm Beach, Florida, 33407
Pfizer Investigational Site
West Palm Beach, Florida, 33409
Pfizer Investigational Site
West Palm Beach, Florida, 33417
Pfizer Investigational Site
West Reading, Pennsylvania, 19611
Pfizer Investigational Site
Wheat Ridge, Colorado, 80033
Pfizer Investigational Site
Wheaton, Maryland, 20902
Pfizer Investigational Site
Whittier, California, 90602
Pfizer Investigational Site
Winston-Salem, North Carolina, 27103
Pfizer Investigational Site
Wyomissing, Pennsylvania, 19610
Pfizer Investigational Site
Yukon, Oklahoma, 73099
Canada22 sites
Pfizer Investigational Site
Calgary, Alberta, T2N 4Z6
Pfizer Investigational Site
Gatineau, Quebec, J8Y 6S9
Pfizer Investigational Site
Hamilton, Ontario, L8N 1Y2
Pfizer Investigational Site
Hawkesbury, Ontario, K6A 1A1
Pfizer Investigational Site
Hawkesbury, Ontario, K6A 3B2
Pfizer Investigational Site
London, Ontario, N6A 4V2
Pfizer Investigational Site
Montreal, Quebec, H2L 1S6
Pfizer Investigational Site
Montreal, Quebec, H2X 1N8
Pfizer Investigational Site
Pointe-Claire, Quebec, H9R 4S3
Pfizer Investigational Site
Québec, Quebec, G1S 2L6
Pfizer Investigational Site
Québec, Quebec, G1V 3M7
Pfizer Investigational Site
Saskatoon, Saskatchewan, S7K 0H6
Pfizer Investigational Site
Saskatoon, Saskatchewan, S7K 1N4
Pfizer Investigational Site
Sherbrooke, Quebec, J1H 4J6
Pfizer Investigational Site
Toronto, Ontario, M5C 1R6
Pfizer Investigational Site
Toronto, Ontario, M5C 2T2
Pfizer Investigational Site
Toronto, Ontario, M5G 1E2
Pfizer Investigational Site
Toronto, Ontario, MB5 1W8
Pfizer Investigational Site
Trois-Rivières, Quebec, G8Z 1Y2
Pfizer Investigational Site
Vancouver, British Columbia, V5Z 2N6
Pfizer Investigational Site
Vancouver, British Columbia, V6H 3X8
Pfizer Investigational Site
Winnipeg, Manitoba, R3A 1M3
Poland17 sites
Pfizer Investigational Site
Katowice, Poland, 40-084
Pfizer Investigational Site
Krakow, Krakow, 30-510
Pfizer Investigational Site
Krakow, 30-007
Pfizer Investigational Site
Krakow, 30-017
Pfizer Investigational Site
Krakow, 30-224
Pfizer Investigational Site
Krakow, 31-501
Pfizer Investigational Site
Lublin, 20-090
Pfizer Investigational Site
Warsaw, Poland, 03-335
Pfizer Investigational Site
Warsaw, 00-315
Pfizer Investigational Site
Warsaw, 00-418
Pfizer Investigational Site
Warsaw, 00-655
Pfizer Investigational Site
Warsaw, 00-699
Pfizer Investigational Site
Warsaw, 00-909
Pfizer Investigational Site
Warsaw, 02-341
Pfizer Investigational Site
Warsaw, 02-796
Pfizer Investigational Site
Warsaw, 04-730
Pfizer Investigational Site
Wroclaw, Poland, 50-088
South Africa13 sites
Pfizer Investigational Site
Bedford Gardens
Pfizer Investigational Site
Groenkloof, Pretoria
Pfizer Investigational Site
Johannesburg, South Africa, 2193
Pfizer Investigational Site
Johannesburg, 2193
Pfizer Investigational Site
Johannesburg, 2196
Pfizer Investigational Site
Johannesburg
Pfizer Investigational Site
Parow, 7500
Pfizer Investigational Site
Parow
Pfizer Investigational Site
Pretoria, South Africa, 0181
Pfizer Investigational Site
Pretoria, 0042
Pfizer Investigational Site
Pretoria
Pfizer Investigational Site
Somerset West
Pfizer Investigational Site
Stellenbosch
Russia12 sites
Pfizer Investigational Site
Moscow, 101990
Pfizer Investigational Site
Moscow, 107014
Pfizer Investigational Site
Moscow, 115522
Pfizer Investigational Site
Moscow, 117036
Pfizer Investigational Site
Moscow, 119002
Pfizer Investigational Site
Moscow, 121356
Pfizer Investigational Site
Moscow, 127299
Pfizer Investigational Site
Moscow, 129010
Pfizer Investigational Site
Saint Petersburg, 1190068
Pfizer Investigational Site
Saint Petersburg, 190068
Pfizer Investigational Site
Saint Petersburg, 194291
Pfizer Investigational Site
Saint Petersburg, 199034
Bulgaria11 sites
Pfizer Investigational Site
Pleven, 5800
Pfizer Investigational Site
Plovdiv, Bulgaria, 4002
Pfizer Investigational Site
Plovdiv, 4002
Pfizer Investigational Site
Sofia, Bulgaria, 1301
Pfizer Investigational Site
Sofia, Bulgaria, 1431
Pfizer Investigational Site
Sofia, Bulgaria, 1504
Pfizer Investigational Site
Sofia, 1301
Pfizer Investigational Site
Sofia, 1303
Pfizer Investigational Site
Sofia, 1407
Pfizer Investigational Site
Sofia, 1431
Pfizer Investigational Site
Sofia, 1504
Finland9 sites
Pfizer Investigational Site
Jyväskylä, FIN, 40100
Pfizer Investigational Site
Jyväskylä, 40700
Pfizer Investigational Site
Jyväskylä, FIN-40100
Pfizer Investigational Site
Kuopio, 70210
Pfizer Investigational Site
Kuopio, 70211
Pfizer Investigational Site
Kuopio, FIN-70211
Pfizer Investigational Site
Lahti
Pfizer Investigational Site
Oulu, Finland, 90 100
Pfizer Investigational Site
Turku, 20100
Romania7 sites
Pfizer Investigational Site
Bucharest, 050521
Pfizer Investigational Site
Bucharest, 7000
Pfizer Investigational Site
Bucharest, 70231
Pfizer Investigational Site
Bucharesti, 7000
Pfizer Investigational Site
Cluj-Napoca, Napoca, 400000
Pfizer Investigational Site
Cluj-Napoca, 400349
Pfizer Investigational Site
Iași, Iaşi, 700111
Belgium6 sites
Pfizer Investigational Site
Diepenbeek, 3590
Pfizer Investigational Site
Genk, 3600
Pfizer Investigational Site
Ghent, Belgium, 9000
Pfizer Investigational Site
Leuven, 3000
Pfizer Investigational Site
Liège, Liege, 4000
Pfizer Investigational Site
Schiepsebos, 6
Brazil6 sites
Pfizer Investigational Site
Duque de Caxias - Cuiaba, Mato Grosso, 78043-306
Pfizer Investigational Site
Goiânia, Goiás, 74175-080
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro, 20020-020
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro, 22271-100
Pfizer Investigational Site
SĂŁo Paulo, SĂŁo Paulo, 04020-060
Pfizer Investigational Site
Sorocaba, SĂŁo Paulo, 18095-450
Netherlands6 sites
Pfizer Investigational Site
Amsterdam, HV, 1081
Pfizer Investigational Site
Eindhoven, 5611 NJ
Pfizer Investigational Site
Emmen, Drenthe, 7824 AA
Pfizer Investigational Site
Nijmegen, GA, 6525
Pfizer Investigational Site
Nijmegen, SZ, 6532
Pfizer Investigational Site
Rotterdam, 3001 HG
Norway6 sites
Pfizer Investigational Site
Bergen, NO-5094
Pfizer Investigational Site
Hamar, 2317
Pfizer Investigational Site
Oslo, NO-0164
Pfizer Investigational Site
Oslo, NO-0176
Pfizer Investigational Site
Trondheim, 7006
Pfizer Investigational Site
Trondheim, NO-7006
Australia5 sites
Pfizer Investigational Site
Concord, New South Wales, 2139
Pfizer Investigational Site
Herston, QLD 4029
Pfizer Investigational Site
Keswick
Pfizer Investigational Site
Nedlands, Western Australia, 6009
Pfizer Investigational Site
St Leonards, New South Wales, 2065
Slovakia5 sites
Pfizer Investigational Site
Bratislava, 826 06
Pfizer Investigational Site
Bratislava, 833 01
Pfizer Investigational Site
Bratislava, 83301
Pfizer Investigational Site
Bratislava, 851 07
Pfizer Investigational Site
Piešťany, Slovak Republic
Spain5 sites
Pfizer Investigational Site
Madrid, Madrid, 28046
Pfizer Investigational Site
Madrid, Spain, 28009
Pfizer Investigational Site
Madrid, 28006
Pfizer Investigational Site
Madrid, 28009
Pfizer Investigational Site
Madrid, 28040
Estonia4 sites
Pfizer Investigational Site
Tallinn, 10128
Pfizer Investigational Site
Tartu, 50410
Pfizer Investigational Site
Tartu, 51010
Pfizer Investigational Site
Tartu
Hungary4 sites
Pfizer Investigational Site
Békéscsaba, 5600
Pfizer Investigational Site
H-6720 Szeged
Pfizer Investigational Site
Kecskemét, 6000
Pfizer Investigational Site
MakĂł, 6900
Italy4 sites
Pfizer Investigational Site
Roma, 00136
Pfizer Investigational Site
Roma, 00168
Pfizer Investigational Site
Roma, 00189
Pfizer Investigational Site
Siena, 53100
New Zealand4 sites
Pfizer Investigational Site
Auckland
Pfizer Investigational Site
Christchurch, NZ, 8143
Pfizer Investigational Site
Dunedin
Pfizer Investigational Site
Milford, Auckland
Denmark3 sites
Pfizer Investigational Site
Aalborg, 9000
Pfizer Investigational Site
Ballerup Municipality, 2750
Pfizer Investigational Site
Vejle, 7100
France3 sites
Pfizer Investigational Site
Lyon, 69437
Pfizer Investigational Site
Orléans, 45032
Pfizer Investigational Site
Paris, 75015
Germany3 sites
Pfizer Investigational Site
Berlin, 12200
Pfizer Investigational Site
MĂĽnchen, 80809
Pfizer Investigational Site
Zerbst, 39261
Hong Kong3 sites
Pfizer Investigational Site
Hong Kong
Pfizer Investigational Site
PRC
Pfizer Investigational Site
Sai Ying Pung
Lithuania3 sites
Pfizer Investigational Site
Kaunas, LT-50009
Pfizer Investigational Site
Vilnius, LT-04130
Pfizer Investigational Site
Vilnius, LT-10318
Mexico3 sites
Pfizer Investigational Site
Mexico City, 03100
Pfizer Investigational Site
Mexico City, 11800
Pfizer Investigational Site
Seccion de Lomas Verdes, State of Mexico, CP 53120
Croatia2 sites
Pfizer Investigational Site
Zadar, 23000
Pfizer Investigational Site
Zagreb, 10000
About this study
Official title: Fracture Incidence Reduction And Safety Of TSE-424 (Bazedoxifene Acetate) Compared To Placebo And Raloxifene In Osteoporotic Postmenopausal Women
The purpose of this study is to determine whether bazedoxifene acetate is safe and effective in the treatment of osteoporosis in postmenopausal women.
- Conditions
- Osteoporosis
- Being tested
- Bazedoxifene Acetate, Placebo
- Keywords
- Osteoporosis, Postmenopause
- Medical subject headings
- Osteoporosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bazedoxifene AcetateDrug
BZA 20mg, daily, oral
PlaceboOther
Placebo, daily, oral
| Study group | Role | What they receive |
|---|---|---|
| A | Active comparator | Not described Receives: Drug: Bazedoxifene Acetate |
| B | Placebo comparator | Not described Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With New Vertebral Fractures Through Month 36
New vertebral fracture: decrease in anterior, mid, or posterior vertebral (vt) height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.
Measured: Baseline through Month 36
Percentage of Participants With New Vertebral Fractures Through Month 60
New vertebral fracture: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.
Measured: Baseline through Month 60
Percentage of Participants With New Vertebral Fractures Through Month 84
New vertebral fracture: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.
Measured: Baseline through Month 84
Secondary outcomes (57)
Incidence of Breast Cancer Through Month 36
Incidence of breast cancer was defined as the number of participants with breast cancer diagnosis by the time point of interest divided by the number of participants included in the analysis. The reported rate was rescaled to reflect average follow-up time per 1000 women (1000 multiplied by number of cases divided by total follow-up time).
Measured: Baseline through Month 36
Incidence of Breast Cancer Through Month 60
Incidence of breast cancer was defined as the number of participants with breast cancer diagnosis by the time point of interest divided by the number of participants included in the analysis. The reported rate was rescaled to reflect average follow-up time per 1000 women (1000 multiplied by number of cases divided by total follow-up time).
Measured: Baseline through Month 60
Incidence of Breast Cancer Through Month 84
Incidence of breast cancer was defined as the number of participants with breast cancer diagnosis by the time point of interest divided by the number of participants included in the analysis. The reported rate was rescaled to reflect average follow-up time per 1000 women (1000 multiplied by number of cases divided by total follow-up time).
Measured: Baseline through Month 84
Percentage of Participants With New Clinical Vertebral Fractures Through Month 36
A new clinical vertebral fracture was defined as a new fracture found at any time because of back pain suggestive of fracture(s). New Clinical vertebral fractures were verified with radiographic assessment using both semi-quantitative and quantitative morphometric assessment: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 mm or more from base to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from T4 to L4, provided vertebra was not fractured at base.
Measured: Baseline through Month 36
Percentage of Participants With New Clinical Vertebral Fractures Through Month 60
A new clinical vertebral fracture was defined as a new fracture found at any time because of back pain suggestive of fracture(s). New Clinical vertebral fractures were verified with radiographic assessment using both semi-quantitative and quantitative morphometric assessment: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 mm or more from base to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from T4 to L4, provided vertebra was not fractured at base.
Measured: Baseline through Month 60
Percentage of Participants With New Clinical Vertebral Fractures Through Month 84
A new clinical vertebral fracture was defined as a new fracture found at any time because of back pain suggestive of fracture(s). New Clinical vertebral fractures were verified with radiographic assessment using both semi-quantitative and quantitative morphometric assessment: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 mm or more from base to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from T4 to L4, provided vertebra was not fractured at base.
Measured: Baseline through Month 84
Number of Participants With Worsening Vertebral Fractures Through Month 36
A worsening vertebral fracture was defined as a decrease in anterior, mid, or posterior vertebral height of at least 20% and at least 4 mm as evaluated by quantitative morphometric assessment, and a grade change of at least 1 as rated by a radiologist using the semi-quantitative rating scale. It can occur only in a vertebra that was fractured at baseline.
Measured: Baseline through Month 36
Number of Participants With Worsening Vertebral Fractures Through Month 60
A worsening vertebral fracture was defined as a decrease in anterior, mid, or posterior vertebral height of at least 20% and at least 4 mm as evaluated by quantitative morphometric assessment, and a grade change of at least 1 as rated by a radiologist using the semi-quantitative rating scale. It can occur only in a vertebra that was fractured at baseline.
Measured: Baseline through Month 60
Number of Participants With Worsening Vertebral Fractures Through Month 84
A worsening vertebral fracture was defined as a decrease in anterior, mid, or posterior vertebral height of at least 20% and at least 4 mm as evaluated by quantitative morphometric assessment, and a grade change of at least 1 as rated by a radiologist using the semi-quantitative rating scale. It can occur only in a vertebra that was fractured at baseline.
Measured: Baseline through Month 84
Percentage of Participants With Non-vertebral Fractures Through Month 36
Non-vertebral fractures were determined by direct questioning at each clinic visit after medication therapy begins. Osteoporosis-related, hip and wrist fractures were summarized.
Measured: Baseline through Month 36
Percentage of Participants With Non-vertebral Fractures Through Month 60
Non-vertebral fractures were determined by direct questioning at each clinic visit after medication therapy begins. Osteoporosis-related, hip and wrist fractures were summarized.
Measured: Baseline through Month 60
Percentage of Participants With Non-vertebral Fractures Through Month 84
Non-vertebral fractures were determined by direct questioning at each clinic visit after medication therapy begins. Osteoporosis-related, hip and wrist fractures were summarized.
Measured: Baseline through Month 84
Change From Baseline in Height at Month 36
Height was measured 3 times using standardized Harpenden stadiometer (height based on the middle stadiometer reading was recorded).
Measured: Baseline, Month 36
Change From Baseline in Height at Month 60
Height was measured 3 times using standardized Harpenden stadiometer (height based on the middle stadiometer reading was recorded).
Measured: Baseline, Month 60
Change From Baseline in Height at Month 84
Height (cm) was measured 3 times using standardized Harpenden stadiometer (height based on the middle stadiometer reading was recorded).
Measured: Baseline, Month 84
Percent Change From Baseline in Bone Mineral Density (BMD) at Month 6, 12, 18, 24 and 36
BMD of lumbar spine (Lu Sp) and hip (total hip [Tl Hp], femoral neck [Fe Ne] and femur trochanter [Fe Tr]) was evaluated by dual-energy x-ray absorptiometry (DXA). The left hip was evaluated unless prevented by pathology, in which case the right hip was evaluated throughout the study. Results were scored as T score, defined as BMD at the site when compared to the young normal reference mean. Normal BMD is a T-score of -1.0 or higher.
Measured: Baseline, Months 6, 12, 18, 24, 36
Percent Change From Baseline in Bone Mineral Density (BMD) at Months 48, 60
BMD of lumbar spine (Lu Sp) and hip (total hip [Tl Hp], femoral neck [Fe Ne] and femur trochanter [Fe Tr]) was evaluated by dual-energy x-ray absorptiometry (DXA). The left hip was evaluated unless prevented by pathology, in which case the right hip was evaluated throughout the study. Results were scored as T score, defined as BMD at the site when compared to the young normal reference mean. Normal BMD is a T-score of -1.0 or higher.
Measured: Baseline, Month 48, 60
Percent Change From Baseline in Bone Mineral Density (BMD) at Months 72 and 84
BMD of lumbar spine (Lu Sp) and hip (total hip [Tl Hp], femoral neck [Fe Ne] and femur trochanter [Fe Tr]) was evaluated by dual-energy x-ray absorptiometry (DXA). The left hip was evaluated unless prevented by pathology, in which case the right hip was evaluated throughout the study. Results were scored as T score, defined as BMD at the site when compared to the young normal reference mean. Normal BMD is a T-score of -1.0 or higher.
Measured: Baseline, Month 72, 84
Percent Change From Baseline in Osteocalcin at Month 3, 6 and 12
Osteocalcin is a biochemical marker of bone formation. Blood samples were collected to evaluate osteocalcin levels.
Measured: Baseline, Months 3, 6, 12
Percent Change From Baseline in Osteocalcin at Months 36 and 60
Osteocalcin is a biochemical marker of bone formation. Blood samples were collected to evaluate osteocalcin levels.
Measured: Baseline, Months 36, 60
Percent Change From Baseline in Osteocalcin at Months 72 and 84
Osteocalcin is a biochemical marker of bone formation. Blood samples were collected to evaluate osteocalcin levels.
Measured: Baseline, Months 72, 84
Percent Change From Baseline in C-telopeptide (CTx) at Month 3, 6 and 12
C-telopeptide is a biochemical marker of bone formation. Blood samples were collected to evaluate C-telopeptide levels.
Measured: Baseline, Months 3, 6, 12
Percent Change From Baseline in C-telopeptide (CTx) at Months 36 and 60
C-telopeptide is a biochemical marker of bone formation. Blood samples were collected to evaluate C-telopeptide levels.
Measured: Baseline, Months 36, 60
Percent Change From Baseline in C-telopeptide (CTx) at Months 72 and 84
C-telopeptide is a biochemical marker of bone formation. Blood samples were collected to evaluate C-telopeptide levels.
Measured: Baseline, Months 72, 84
Percent Change From Baseline in Lipid Parameters at Months 6, 12, 24 and 36
Lipid parameters evaluated included total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL), triglyceride (TG), high-density lipoprotein fraction 2 (HDL2) and high-density lipoprotein fraction 3 (HDL3).
Measured: Baseline, Months 6, 12, 24, 36
Bone Histomorphometric Indices at Month 36: BV, OV, OS, OcS, ObS, MS, ES, OMS, CP
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Percentage of following indices (volume,surface,porosity) was calculated:Bone Volume(BV), Osteoid Volume(OV), Osteoid Surface(OS), Osteoclast Surface(OcS), Osteoblast Surface(ObS), Mineralizing surface(MS), Eroded Surface(ES), Osteoid Mineralizing surface(OMS), Cortical porosity(CP).
Measured: Month 36
Bone Histomorphometric Indices at Month 60: BV, OV, OS, OcS, ObS, MS, ES, OMS, CP
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Percentage of following indices (volume,surface,porosity) was calculated:Bone Volume(BV), Osteoid Volume(OV), Osteoid Surface(OS), Osteoclast Surface(OcS), Osteoblast Surface(ObS), Mineralizing surface(MS), Eroded Surface(ES), Osteoid Mineralizing surface(OMS), Cortical porosity(CP).
Measured: Month 60
Bone Histomorphometric Indices at Month 36: WTh, OTh, TbTh, TbSp and CTh
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated indices included: Wall Thickness (WTh), Osteoid Thickness (OTh), Trabecular Thickness (TbTh), Trabecular Separation (TbSp) and Cortical thickness (CTh). Trabecular separation defined as the thickness of the spaces as defined by binarization within the volume of interest.
Measured: Month 36
Bone Histomorphometric Indices at Month 60: WTh, OTh, TbTh, TbSp and CTh
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated indices included: WTh, OTh, TbTh, TbSp and CTh. Trabecular separation defined as the thickness of the spaces as defined by binarization within the volume of interest.
Measured: Month 60
Bone Histomorphometric Indices at Month 36: Total Surface (Goldner Slide) [TSG]
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated indices included: Total Surface (Goldner Slide) [TSG]. All specimens were demineralized and subjected to staining procedures (Goldner's staining). Slides were analyzed using light microscopy for total surface area, the surface area that consisted of bone and the surface area that consisted of graft material (all in mm^2 and expressed as percent (%) of the total surface.
Measured: Month 36
Bone Histomorphometric Indices at Month 60: TSG
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated indices included: Total Surface (Goldner Slide) [TSG]. All specimens were demineralized and subjected to staining procedures (Goldner's staining). Slides were analyzed using light microscopy for total surface area, the surface area that consisted of bone and the surface area that consisted of graft material (all in mm^2 and expressed as percent (%) of the total surface.
Measured: Month 60
Bone Histomorphometric Indices at Month 36: TtAr
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated variable: Tissue Area (TtAr). Tissue area comprised of the porous calcified substance from which bones were made.
Measured: Month 36
Bone Histomorphometric Indices at Month 60: TtAr
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated variable: Tissue Area (TtAr). Tissue area comprised of the porous calcified substance from which bones were made.
Measured: Month 60
Bone Histomorphometric Indices at Month 36: BFP, RP and RmP
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated indices included: Bone Formation Period (BFP), Resorption Period (RP), Remodeling Period (RmP).
Measured: Month 36
Bone Histomorphometric Indices at Month 60: BFP, RP and RmP
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated indices included: Bone Formation Period (BFP), Resorption Period (RP), Remodeling Period (RmP).
Measured: Month 60
Bone Histomorphometric Indices at Month 36: SuD
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Surface Density (SuD).
Measured: Month 36
Bone Histomorphometric Indices at Month 60: SuD
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Surface Density (SuD).
Measured: Month 60
Bone Histomorphometric Indices at Month 36: BFRTS
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Bone Form Rate (BFR)-Total Surface Reference (BFRTS). BFR accounts the bone surface which is actively mineralizing, which depends on the number of osteoblasts that are active. BFR= Fraction of mineralizing surface and bone surface multiplied by mineralization apposition rate (MAR).
Measured: Month 36
Bone Histomorphometric Indices at Month 60: BFRTS
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Bone Form Rate (BFR)-Total Surface Reference (BFRTS). BFR accounts the bone surface which is actively mineralizing, which depends on the number of osteoblasts that are active. BFR= Fraction of mineralizing surface and bone surface multiplied by mineralization apposition rate (MAR).
Measured: Month 60
Bone Histomorphometric Indices at Month 36: ACF
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Activation Frequency (ACF). The total period (TP) is the duration between the beginning of one formation period (FP) and the beginning of the next FP. The number of times per year that this spot begins the FP is the activation frequency (ACF).
Measured: Month 36
Bone Histomorphometric Indices at Month 60: ACF
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Activation Frequency (ACF). The total period (TP) is the duration between the beginning of one formation period (FP) and the beginning of the next FP. The number of times per year that this spot begins the FP is the activation frequency (ACF).
Measured: Month 60
Bone Histomorphometric Indices at Month 36: Mlt
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Mineralization Lag Time (Mlt). Mineralization lag time was the lag between the time osteoid was formed and the mineral was added.
Measured: Month 36
Bone Histomorphometric Indices at Month 60: Mlt
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Mineralization Lag Time (Mlt). Mineralization lag time was the lag between the time osteoid was formed and the mineral was added.
Measured: Month 60
Bone Histomorphometric Indices at Month 36: MAR
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Mineral Apposition Rate (MAR). MAR is the area of new bone formed during the label interval.
Measured: Month 36
Bone Histomorphometric Indices at Month 60: MAR
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Mineral Apposition Rate (MAR). MAR is the area of new bone formed during the label interval.
Measured: Month 60
Bone Histomorphometric Indices at Month 36: TbN
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Trabecular Number (TbN). TbN= Ratio of bone volume to tissue volume divided by trabecular thickness.
Measured: Month 36
Bone Histomorphometric Indices at Month 60: TbN
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Trabecular Number (TbN). TbN= Ratio of bone volume to tissue volume divided by trabecular thickness.
Measured: Month 60
Bone Histomorphometric Indices at Month 36: BFRBV
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Bone Formation Rate (BFR)-Bone Volume Reference (BFRBV). BFR accounts the bone volume which is actively mineralizing, which depends on the number of osteoblasts that are active. BFR= Fraction of mineralizing volume and bone volume multiplied by mineralization apposition rate (MAR).
Measured: Month 36
Bone Histomorphometric Indices at Month 60: BFRBV
Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Bone Formation Rate (BFR)-Bone Volume Reference (BFRBV). BFR accounts the bone volume which is actively mineralizing, which depends on the number of osteoblasts that are active. BFR= Fraction of mineralizing volume and bone volume multiplied by mineralization apposition rate (MAR).
Measured: Month 60
Women's Health Questionnaire (WHQ)
WHQ is a measure of mid-aged women's emotional and physical health. Consists of 36-item assessing nine domains of physical and emotional health: Depressed mood; Somatic symptoms; Anxiety/fears; Vasomotor symptoms; Sleep problems; Sexual behavior; Menstrual symptoms; Memory/concentration; and Attractiveness. Each item scored on a 4 point scale (yes definitely, yes sometimes, not much, no not at all) reduced to binary option as 0 (no) and 1 (yes). Domain subscale score was calculated as sum of domain items score divided by number of domain items. Total score was calculated as the sum of individual domain subscale score divided by number of domains. Total score range from 0 (absent) to 1 (present), with higher scores indicating more pronounced distress and dysfunction. Baseline values at different time points were considered only for the participants who were evaluable at those time points.
Measured: Baseline
Change From Baseline in Women's Health Questionnaire (WHQ) at Month 12, 24 and 36
WHQ is a measure of mid-aged women's emotional and physical health. Consists of 36-item assessing nine domains of physical and emotional health: Depressed mood; Somatic symptoms; Anxiety/fears; Vasomotor symptoms; Sleep problems; Sexual behavior; Menstrual symptoms; Memory/concentration; and Attractiveness. Each item scored on a 4 point scale (yes definitely, yes sometimes, not much, no not at all) reduced to binary option as 0 (no) and 1 (yes). Domain subscale score was calculated as sum of domain items score divided by number of domain items. Total score was calculated as the sum of individual domain subscale score divided by number of domains. Total score range from 0 (absent) to 1 (present), with higher scores indicating more pronounced distress and dysfunction.Baseline values at different time points were considered only for the participants who were evaluable at those time points.
Measured: Baseline, Months 12, 24, 36
European Foundation for Osteoporosis Quality of Life Questionnaire (QUALEFFO)
QUALEFFO is an osteoporosis-specific health instrument developed specifically for participants with vertebral deformities used to evaluate the effect of back pain and treatment on quality of life. The QUALEFFO questionnaire includes 41 items in 5 domains: pain, physical function, social function, general health perception, and mental function. The total score is calculated according to the scoring algorithm developed by the International Osteoporosis Foundation. Total scores are reported from 0 to 100, with lower scores corresponding to better quality of life. Baseline values at different time points were considered only for the participants who were evaluable at those time points.
Measured: Baseline
Change From Baseline in European Foundation for Osteoporosis Quality of Life Questionnaire (QUALEFFO) at Month 12, 24 and 36
QUALEFFO is an osteoporosis-specific health instrument developed specifically for participants with vertebral deformities used to evaluate the effect of back pain and treatment on quality of life. The QUALEFFO questionnaire includes 41 items in 5 domains: pain, physical function, social function, general health perception, and mental function. The total score is calculated according to the scoring algorithm developed by the International Osteoporosis Foundation. Total scores are reported from 0 to 100, with lower scores corresponding to better quality of life. Baseline values at different time points were considered only for the participants who were evaluable at those time points.
Measured: Baseline, Months 12, 24, 36
Euro Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Baseline values at different time points were considered only for the participants who were evaluable at those time points.
Measured: Baseline
Change From Baseline in Euro Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Month 12, 24 and 36
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Baseline values at different time points were considered only for the participants who were evaluable at those time points.
Measured: Baseline, Months 12, 24, 36
Euro Quality of Life-5 Dimensions (EQ-5D)- Health State Profile Utility Score
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Baseline values at different time points were considered only for the participants who were evaluable at those time points.
Measured: Baseline
Change From Baseline in Euro Quality of Life-5 Dimensions (EQ-5D)- Health State Profile Utility Score at Month 12, 24 and 36
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Baseline values at different time points were considered only for the participants who were evaluable at those time points.
Measured: Baseline, Months 12, 24, 36
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Sep 2005 (estimated)
- Study startDec 2001
- Primary completionSep 2010
- Study completionSep 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for OsteoporosisStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 7,609 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00205777
- Sponsor's protocol ID
- 3068A1-301
- Other IDs
- B1781001
- Status last verified
- Feb 2013
- First submitted
- 16 Sep 2005
- Last updated
- 10 Apr 2013
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Christiansen C, Chesnut CH 3rd, Adachi JD, Brown JP, Fernandes CE, Kung AW, Palacios S, Levine AB, Chines AA, Constantine GD. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord. 2010 Jun 22;11:130. doi: 10.1186/1471-2474-11-130.
PubMed 20569451
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Fracture Incidence Reduction And Safety Of TSE-424 (Bazedoxifene Acetate) Compared To Placebo And Raloxifene In Osteoporotic Postmenopausal Women
- ClinicalTrials.gov ID
- NCT00205777
- Acronym / sponsor ID
- 3068A1-301
- Conditions
- Osteoporosis
- Keywords
- Osteoporosis, Postmenopause
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 7,609 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Dec 2001
- Primary completion
- Sep 2010 (actual)
- Study completion
- Sep 2010 (actual)
- First posted
- 20 Sep 2005 (estimated)
- Results
- Posted 10 Apr 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether bazedoxifene acetate is safe and effective in the treatment of osteoporosis in postmenopausal women.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| A | Active comparator | Drug: Bazedoxifene Acetate |
| B | Placebo comparator | Other: Placebo |
Who may qualify
- Ages
- 55 to 80 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Must be at least 2 years postmenopausal
- Osteoporotic subjects without vertebral fracture who meet BMD criteria, or Osteoporotic subjects with vertebral fracture
Key exclusion criteria (4 listed)
- Diseases that may affect bone metabolism
- Vasomotor symptoms requiring treatment
- Known history or suspected cancer of the breast
- Active or past history of venous thromboembolic events
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bazedoxifene AcetateBZA 20mg, daily, oral | Drug | A |
| PlaceboPlacebo, daily, oral | Other | B |
Primary outcome
Percentage of Participants With New Vertebral Fractures Through Month 36
Time frame: Baseline through Month 36
New vertebral fracture: decrease in anterior, mid, or posterior vertebral (vt) height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.
Percentage of Participants With New Vertebral Fractures Through Month 60
Time frame: Baseline through Month 60
New vertebral fracture: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.
Percentage of Participants With New Vertebral Fractures Through Month 84
Time frame: Baseline through Month 84
New vertebral fracture: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.
57 secondary outcomes
Incidence of Breast Cancer Through Month 36
Time frame: Baseline through Month 36
Incidence of Breast Cancer Through Month 60
Time frame: Baseline through Month 60
Incidence of Breast Cancer Through Month 84
Time frame: Baseline through Month 84
Percentage of Participants With New Clinical Vertebral Fractures Through Month 36
Time frame: Baseline through Month 36
Percentage of Participants With New Clinical Vertebral Fractures Through Month 60
Time frame: Baseline through Month 60
Percentage of Participants With New Clinical Vertebral Fractures Through Month 84
Time frame: Baseline through Month 84
Number of Participants With Worsening Vertebral Fractures Through Month 36
Time frame: Baseline through Month 36
Number of Participants With Worsening Vertebral Fractures Through Month 60
Time frame: Baseline through Month 60
Number of Participants With Worsening Vertebral Fractures Through Month 84
Time frame: Baseline through Month 84
Percentage of Participants With Non-vertebral Fractures Through Month 36
Time frame: Baseline through Month 36
Percentage of Participants With Non-vertebral Fractures Through Month 60
Time frame: Baseline through Month 60
Percentage of Participants With Non-vertebral Fractures Through Month 84
Time frame: Baseline through Month 84
Change From Baseline in Height at Month 36
Time frame: Baseline, Month 36
Change From Baseline in Height at Month 60
Time frame: Baseline, Month 60
Change From Baseline in Height at Month 84
Time frame: Baseline, Month 84
Percent Change From Baseline in Bone Mineral Density (BMD) at Month 6, 12, 18, 24 and 36
Time frame: Baseline, Months 6, 12, 18, 24, 36
Percent Change From Baseline in Bone Mineral Density (BMD) at Months 48, 60
Time frame: Baseline, Month 48, 60
Percent Change From Baseline in Bone Mineral Density (BMD) at Months 72 and 84
Time frame: Baseline, Month 72, 84
Percent Change From Baseline in Osteocalcin at Month 3, 6 and 12
Time frame: Baseline, Months 3, 6, 12
Percent Change From Baseline in Osteocalcin at Months 36 and 60
Time frame: Baseline, Months 36, 60
Percent Change From Baseline in Osteocalcin at Months 72 and 84
Time frame: Baseline, Months 72, 84
Percent Change From Baseline in C-telopeptide (CTx) at Month 3, 6 and 12
Time frame: Baseline, Months 3, 6, 12
Percent Change From Baseline in C-telopeptide (CTx) at Months 36 and 60
Time frame: Baseline, Months 36, 60
Percent Change From Baseline in C-telopeptide (CTx) at Months 72 and 84
Time frame: Baseline, Months 72, 84
Percent Change From Baseline in Lipid Parameters at Months 6, 12, 24 and 36
Time frame: Baseline, Months 6, 12, 24, 36
Bone Histomorphometric Indices at Month 36: BV, OV, OS, OcS, ObS, MS, ES, OMS, CP
Time frame: Month 36
Bone Histomorphometric Indices at Month 60: BV, OV, OS, OcS, ObS, MS, ES, OMS, CP
Time frame: Month 60
Bone Histomorphometric Indices at Month 36: WTh, OTh, TbTh, TbSp and CTh
Time frame: Month 36
Bone Histomorphometric Indices at Month 60: WTh, OTh, TbTh, TbSp and CTh
Time frame: Month 60
Bone Histomorphometric Indices at Month 36: Total Surface (Goldner Slide) [TSG]
Time frame: Month 36
Bone Histomorphometric Indices at Month 60: TSG
Time frame: Month 60
Bone Histomorphometric Indices at Month 36: TtAr
Time frame: Month 36
Bone Histomorphometric Indices at Month 60: TtAr
Time frame: Month 60
Bone Histomorphometric Indices at Month 36: BFP, RP and RmP
Time frame: Month 36
Bone Histomorphometric Indices at Month 60: BFP, RP and RmP
Time frame: Month 60
Bone Histomorphometric Indices at Month 36: SuD
Time frame: Month 36
Bone Histomorphometric Indices at Month 60: SuD
Time frame: Month 60
Bone Histomorphometric Indices at Month 36: BFRTS
Time frame: Month 36
Bone Histomorphometric Indices at Month 60: BFRTS
Time frame: Month 60
Bone Histomorphometric Indices at Month 36: ACF
Time frame: Month 36
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2013.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 20569451Christiansen C, Chesnut CH 3rd, Adachi JD, Brown JP, Fernandes CE, Kung AW, Palacios S, Levine AB, Chines AA, Constantine GD. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord. 2010 Jun 22;11:130. doi: 10.1186/1471-2474-11-130.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Osteoporosis
RecruitingObservational study
A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment of Vertebral Compression Fractures of (Suspected) Osteoporotic Origin.
Vertebra Compression Fracture
Active, not recruitingObservational study
The Impact of Osteosarcopenia on Falls, Kinesiophobia, and Quality of Life in Postmenopausal Women
Osteosarcopenia, Sarcopenia
Active, not recruitingPhase 2
TCM Formula vs. HMB in Pre-Frail Elders: Muscle Strength and Bone Status
Pre-Frailty, Sarcopenia
Not yet recruitingPhase 4
Romosozumab and Denosumab Combination Therapy for Osteoporosis
Postmenopausal Osteoporosis
RecruitingObservational study
Assessment and Comparison of Osteoporosis Risk Factors After Stroke
Stroke, Osteoporosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
375 sites in 30 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Bazedoxifene Acetate in people with Osteoporosis, run by Pfizer at 375 sites in 30 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Apr 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 375 sites in United States, Canada, Poland, South Africa, Russia and 25 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Apr 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With New Vertebral Fractures Through Month 36 (time frame: Baseline through Month 36). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00205777, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2013.